首页> 外文期刊>International journal of hematology-oncology and stem cell research. >Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: A Controlled, Cross-Sectional Study
【24h】

Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: A Controlled, Cross-Sectional Study

机译:血红素加氧酶-1基因启动子中(GT)n重复与急性白血病患者3年生存率的关联:一项对照横断面研究

获取原文
           

摘要

Background: Acute leukemia is a common pediatric cancer. Novel strategies for treatment of acute leukemia have been developed, but treatment resistance has remained as the most problematic issue. It is hypothesized that the HO-1 gene up-regulation is responsible for tumor resistance to chemotherapy or radiotherapy-induced apoptosis. HO-1 expression levels have been related to (GT)n microsatellite polymorphisms in the location of its promoter.This study designed to compare allelic frequencies of (GT)n microsatellite polymorphisms in HO-1 gene between acute leukemia patients and healthy controls. Indeed, 3-year disease-free survival was also evaluated.Materials and Methods: The study included 63 acute leukemia patients and 70 healthy infants. We used patient’s medical records to collect data regarding the post-chemotherapy survival. The number of GT repeats in HO-1 promoter was determined by an ABI 3100 sequencer.Results: The HO-1 GT repeats ranged from 14 to 34 with peaks at 27 repeats in both cases and controls. Children with longer alleles ((GT)n ≥ 27) had enhanced 3-year survival rate after treatment with chemotherapy or radiotherapy (P0.05).Conclusion: Although no significant differences were observed between leukemia patients and controls regarding allelic frequency, we found elevated frequency of “LL” genotype in leukemia patients with good 3-year surveillance. Radiotherapy and chemotherapy might elevate the expression levels of HO-1 with subsequent increased resistance of leukemia patients to therapy.
机译:背景:急性白血病是一种常见的小儿癌症。已经开发出治疗急性白血病的新策略,但是治疗耐药性仍然是最成问题的问题。假设HO-1基因上调是肿瘤对化学疗法或放射疗法诱导的细胞凋亡的抵抗力的原因。 HO-1表达水平与其启动子位置的(GT)n微卫星多态性有关。本研究旨在比较急性白血病患者和健康对照者HO-1基因中(GT)n微卫星多态性的等位基因频率。实际上,还评估了3年无病生存期。材料与方法:该研究包括63例急性白血病患者和70例健康婴儿。我们使用了患者的病历来收集有关化疗后存活率的数据。结果:HO-1 GT重复序列在HO-1启动子中的数量由ABI 3100测序仪确定。结果:HO-1 GT重复序列的范围从14到34,在两种情况下和对照中的峰值均为27个重复序列。等位基因较长((GT)n≥27)的儿童在接受化学疗法或放疗后的3年生存率提高了(P <0.05)。结论:尽管在白血病患者和对照组之间,等位基因频率没有显着差异,但我们发现具有良好3年监测的白血病患者中“ LL”基因型的频率升高。放射疗法和化学疗法可能会提高HO-1的表达水平,从而增加白血病患者对治疗的抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号